Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced a conference call and webcast set for May 9, 2023, at 4:30 p.m. ET to discuss its first quarter financial results. The press release detailing these results will be available after the market closes on the same day. Investors can access the live webcast and subsequent archive through the company’s investor website. Arcutis focuses on developing innovative treatments for immune-mediated dermatological diseases, boasting a robust pipeline targeting conditions like psoriasis and atopic dermatitis. Investors are advised to stay tuned for the upcoming earnings call and associated materials.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced that the FDA has accepted its New Drug Application (NDA) for roflumilast foam 0.3% aimed at treating seborrheic dermatitis in individuals aged 9 and older. The FDA set a target action date of December 16, 2023. If approved, this foam would be the first topical treatment for this condition with a new mechanism of action in over two decades. The NDA is supported by positive results from Phase 2 and pivotal Phase 3 trials, with the latter showing a 79.5% success rate in treating patients, compared to 58.0% for the vehicle. Roflumilast foam was well-tolerated with low adverse events. The company aims to address the significant unmet need for effective treatments for seborrheic dermatitis.
Arcutis Biotherapeutics (Nasdaq: ARQT), a leader in immuno-dermatology, announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. The fireside chat is scheduled for April 18, 2023, at 11:45 a.m. ET. Investors and stakeholders can access the webcast via the company’s website, with a replay available for 90 days post-event. Arcutis specializes in innovative therapies for various dermatological conditions such as psoriasis and eczema. The company's commitment to addressing patient needs has led to a robust pipeline of clinical programs targeting immune-mediated skin diseases. This announcement highlights Arcutis’ strategy to engage with investors and showcase its ongoing developments in the field.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced on April 7, 2023, the grant of 83,250 restricted stock units and options for 33,000 shares to 10 newly hired employees. These awards are part of the 2022 Inducement Plan, approved by the Compensation Committee of the Board of Directors. The restricted stock units will vest over four years, with 25% vesting annually, while the stock options will also vest over four years, with 25% vesting after one year and the remainder in monthly installments. The options have an exercise price of $11.15 per share. Arcutis is committed to developing innovative solutions for immune-mediated dermatological conditions, backed by a robust pipeline of clinical programs.